Table 3 Clinical and radiographic variables based on modified RECIST criteria
From: Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
Variable | CR + PR (n = 56) | SD + PD (n = 55) | p-value |
|---|---|---|---|
Child-pugh score | 0.278 | ||
A | 41 (73.2) | 35 (63.6) | |
B | 15 (26.8) | 20 (36.4) | |
BCLC stage | 0.262 | ||
0 | 1 (1.8) | 0 (0) | |
A | 32 (57.1) | 23 (41.8) | |
B | 22 (39.3) | 31 (56.4) | |
C | 1 (1.8) | 1 (1.8) | |
AFP level (ng/mL) | 0.788 | ||
< 20 | 36 (64.3) | 34 (61.8) | |
≥ 20 | 20 (35.7) | 21 (38.2) | |
Pretreatment ANC (109/L) | 2.95 ± 1.38 | 2.72 ± 1.31 | 0.354 |
Pretreatment ALC (109/L) | 1.53 ± 0.81 | 1.44 ± 0.76 | 0.569 |
Pretreatment NLR | 0.200 | ||
< 5 | 55 (98.2) | 50 (90.9) | |
≥ 5 | 1 (1.8) | 5 (9.1) | |
Pretreatment PLT count (109/L) | 138.02 ± 84.68 | 109.02 ± 71.11 | 0.053 |
Pretreatment PLR | 93.25 ± 37.32 | 89.49 ± 84.29 | 0.761 |
Diameter of largest nodule | 0.692 | ||
< 5 cm | 42 (75.0) | 43 (78.2) | |
≥ 5 cm | 14 (25.0) | 12 (21.8) | |
Number of nodules | 0.017 | ||
1 | 33 (58.9) | 20 (36.4) | |
≥ 2 | 23 (41.1) | 35 (63.6) | |
Nodule location in the liver | 0.342 | ||
Right liver | 44 (78.6) | 37 (67.3) | |
Median liver | 6 (10.7) | 7 (12.7) | |
Left liver | 6 (10.7) | 11 (20.0) | |
Irregular margin | 0.003 | ||
Smooth | 32 (57.1) | 16 (29.1) | |
Irregular | 24 (42.9) | 39 (70.9) | |
Arterial peritumoral enhancement | 0.105 | ||
Absent | 53 (94.6) | 47 (85.5) | |
Present | 3 (5.4) | 8 (14.5) | |
Satellite nodules | 0.043 | ||
Absent | 50 (89.3) | 41 (74.5) | |
Present | 6 (10.7) | 14 (25.5) | |
Peripheral lesion | 0.668 | ||
Absent | 12 (21.4) | 10 (18.2) | |
Present | 44 (78.6) | 45 (81.8) | |
Nonrim APHE | 0.987 | ||
Absent | 1 (1.8) | 2 (3.6) | |
Present | 55 (98.2) | 53 (96.4) | |
Nonperipheral washout | 0.727 | ||
Absent | 5 (8.9) | 6 (10.9) | |
Present | 51 (91.1) | 49 (89.1) | |
Radiological capsule | 0.496 | ||
Absent | 12 (21.4) | 9 (16.4) | |
Present | 44 (78.6) | 46 (83.6) | |
Fat in mass | 0.339 | ||
Absent | 36 (64.3) | 40 (72.7) | |
Present | 20 (35.7) | 15 (27.3) | |
Blood products in mass | 0.473 | ||
Absent | 44 (78.6) | 40 (72.7) | |
Present | 12 (21.4) | 15 (27.3) | |
Nodule-in-nodule architecture | 1.000 | ||
Absent | 53 (94.6) | 52 (94.5) | |
Present | 3 (5.4) | 3 (5.5) | |
Mosaic architecture | 0.625 | ||
Absent | 26 (46.4) | 23 (41.8) | |
Present | 30 (53.6) | 32 (58.2) | |
Restricted diffusion | 0.209 | ||
Absent | 4 (7.1) | 8 (14.5) | |
Present | 52 (92.9) | 47 (85.5) | |
Mild-to-moderate T2 hyperintensity | 0.325 | ||
Absent | 4 (7.1) | 7 (12.7) | |
Present | 52 (92.9) | 48 (87.3) |